Crossmark

Successful treatment of multi-hit TP53-mutated myelodysplastic syndromes with erythroid predominance using allogeneic stem cell transplantation and ruxolitinib

Crossref DOI link: https://doi.org/10.1007/s00277-025-06383-1

Published Online: 2025-05-06

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oshima, Seigi

Kanda, Junya

Takeda, June

Sakamoto, Takashi

Mizumoto, Chisaki

Yamashita, Kouhei

Nannya, Yasuhito

Ogawa, Seishi

Takaori-Kondo, Akifumi
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP24ek0510046)

JSPS KAKENHI (JP24K11515)
License Information

Text and Data Mining valid from 2025-05-06

Version of Record valid from 2025-05-06
More Information

Article History

Received: 5 February 2025

Accepted: 22 April 2025

First Online: 6 May 2025

Declarations

:

: Not applicable.

: Informed consent was obtained from the patient for the publication of this case report.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below